# GeneDart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genedart

- Industry: Forestry & Timber
- Headquarters: Beijing, China
- Latest round: Series A (Nov 23, 2024)
- Investors on record: 4

## About

Established in 2021 and based in Ningbo, China, GeneDart is a company dedicated to the development and commercialization of synthetic biology technologies. The company's core team has experience in the field of synthetic biology and has developed its first product that has received FDA approval and other qualifications. In November 2023, the company closed a round of series A funding. In September 2024, GeneDart closed a series A+ funding.

The company develops compound products by building synthetic biology technology platforms, including the development of products such as animal nutrients by utilizing its ability to construct efficient strains and fermentation optimization.

The company generates revenue by developing animal nutrients by utilizing its ability to construct efficient strains and fermentation optimization.

The company will use the series A+ funding for product pipeline development, large-scale mass production, application scenario expansion and global market layout in the field of synthetic biology.

## Funding rounds

- Series A, Nov 23, 2024 — Zhongke Changguang Venture Capital, Shunchuang Industrial Investment
- Series A, Nov 13, 2023 — Green Pine Capital Partners, Sinochem

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- Sinochem (https://capitalatlas.ai/funds/sinochem) — Series A
- Zhongke Changguang Venture Capital (https://capitalatlas.ai/funds/zhongke-changguang-venture-capital) — Series A
- Shunchuang Industrial Investment (https://capitalatlas.ai/funds/shunchuang-industrial-investment) — Series A